Superworth

Harrow price to book ratio HROW

Market value divided by the book value of the company's net assets, since 2012.

Today, Oct 23, 2026
70.1×
10-year median
12.9×
Against its 10-year history
98th
percentile: 0 is its lowest day, 100 its highest
10-year range
3.3× to 101×
Peer median
2.7×

Harrow's price to book ratio is 70.1× as of Oct 23, 2026.

That is above its ten-year median of 12.9×, higher than on 98% of days in the last ten years.

Over that time it ranged from 3.3× in Apr 2020 to 101× in Aug 2026.

The median for 10 large drugmakers of a similar size is 2.7×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far70.1×23.6×101×
202539.5×12.0×39.5×
202420.6×4.4×34.8×
20235.2×4.2×30.3×
202254.4×11.2×57.7×
202114.0×6.3×18.0×
20207.0×3.3×11.4×
20198.3×3.3×35.9×
201827.1×8.8×30.5×
20179.3×4.1×14.7×
201611.7×5.6×27.2×
201529.9×6.3×31.8×
20146.8×1.9×7.7×
20131.8×1.8×8.2×
20126.1×3.2×10.1×

Against its peers

Companies in Drug Manufacturers - General nearest Harrow's size, closest first, today.

CompanyPrice to book ratio
HROWHarrow70.1×
AMPHAmphastar Pharmaceuticals1.4×
OMEROmerosn/m
ABUSArbutus Biopharma3.2×
PCRXPacira BioSciences2.2×
ANABAnaptysbio138×
COLLCollegium Pharmaceutical2.4×
PAHCPhibro Animal Health4.1×
ANIPANI Pharmaceuticals2.8×
CRMDCorMedix1.3×
ZVRAZevra Therapeutics2.7×
Peer median2.7×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Harrow

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.